Factors affecting the outcome of the usage of high-flow nasal cannula on severe or critically ill COVID-19 patients: a multicentric study from a developing nation

Authors

  • Moumita Das Intensive care unit (ICU), 250 Bedded General Hospital, Chattogram-4000, Bangladesh
  • Shuva Das Department of Microbiology, Chittagong Medical College, Chattogram-4203, Bangladesh
  • AFM T Bhuiyan Intensive care unit (ICU), 250 Bedded General Hospital, Chattogram-4000, Bangladesh
  • Sudipta Deb Nath Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka-1000, Bangladesh
  • Rajdeep Biswas Intensive care unit (ICU), 250 Bedded General Hospital, Chattogram-4000, Bangladesh
  • Jitu D Gupta Intensive care unit (ICU), 250 Bedded General Hospital, Chattogram-4000, Bangladesh
  • Anjan Ball Department of Anesthesia and ICU, Chittagong Medical College, Chattogram-4203, Bangladesh
  • Mohammad J Alam Adult ICU, Surgiscope Hospital Ltd., Chattogram-4203, Bangladesh
  • Md H Karim Intensive care unit (ICU), 250 Bedded General Hospital, Chattogram-4000, Bangladesh
  • Ranjan K Nath Department of Anesthesia and ICU, Chittagong Medical College, Chattogram-4203, Bangladesh
  • Ayan Saha Department of Genetic Engineering and Biotechnology, East West University, Dhaka-1212, Bangladesh

DOI:

https://doi.org/10.3329/ajmbr.v7i3.56136

Keywords:

HFNC; COVID-19; ICU; NRM; SpO2

Abstract

In resource-constrained settings, High-Flow Nasal Cannula (HFNC) can reduce the burden on mechanical ventilation in COVID-19 induced Acute Hypoxemic Respiratory Failure (AHRF). The aim was to observe the factors those might affect the outcome of the usage of HFNC on severe/critically ill COVID-19 patients. This is a multicentric prospective observational study. We observed rRT-PCR positive severe/critically ill ICU patients requiring HFNC for more than six hours. Statistical analysis was done to correlate between factors and outcome. Weaning from HFNC was successful in 47.5% of patients. The death rate was higher in ≥ 50 years older (56.50%), and patients with asthma (60.57%), COPD (60.00%), and CKD (68.42%). Fever (91.67%), cough (72.5%), and dyspnea (67.5%) were the most common symptoms. Mortality rates were higher for patients with raised blood sugar, creatinine levels. Severely systemic inflammatory response was seen very high for the expired patients. On HFNC, percent saturation of oxygen (SpO2) and partial pressure of oxygen (PaO2) progression was significantly high for the surviving patients requiring less inspired fraction of oxygen (FiO2%). The survival rate was higher for the patients using both HFNC and non-rebreather mask (NRM) concomitantly. While after HFNC- SpO2% and FiO2% were significantly related with outcome of the HFNC only treated patients, duration of hospital stay and on HFNC- FiO2% affected the HFNC + NRM treated patients’ outcome. HFNC could save more lives of critically ill AHRF patients who otherwise might need invasive or noninvasive ventilation. Some biochemical tests were observed to have association with the prognosis of the disease though HFNC was given to all. Survival benefit of dual HFNC and NRM therapy needs future study.

Asian J. Med. Biol. Res. 2021, 7 (3), 260-272

Downloads

Download data is not yet available.
Abstract
102
PDF
73

Downloads

Published

2021-09-30

How to Cite

Das, M. ., Das, S. ., Bhuiyan, A. T., Nath, S. D. ., Biswas, R. ., Gupta, J. D., Ball, A. ., Alam, M. J., Karim, M. H., Nath, R. K., & Saha, A. (2021). Factors affecting the outcome of the usage of high-flow nasal cannula on severe or critically ill COVID-19 patients: a multicentric study from a developing nation. Asian Journal of Medical and Biological Research, 7(3), 260–272. https://doi.org/10.3329/ajmbr.v7i3.56136

Issue

Vol. 7 No. 3 (2021)

Section

Research Articles

License

Copyright (c) 2021 Moumita Das, Shuva Das, AFM T Bhuiyan, Sudipta Deb Nath, Rajdeep Biswas, Jitu D Gupta, Anjan Ball, Mohammad J Alam, Md H Karim, Ranjan K Nath and Ayan Saha

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms / The author(s) affirm(s) that:

  1. The manuscript submitted is based on authors own research and is original work.
  2. Authors certify that we all participated in the research work and preparation of the manuscript in a substantive way.
  3. Authors also declare that they have read and approved the manuscript.
  4. Authors further declare that the manuscript has not been published in part or full and is not being submitted or considered for publication in part or full elsewhere.
  5. Any material included in the manuscript does not violate copyright or other rights of anyone. 
  6. Authors  also affirm that the article contains no vilifying or unlawful statements and does not contain material or instructions that might cause harm or injury to the Editor-in-Chief/Editors of the Journal and the public.
  7. Authors assure Asian J. Med. Biol. Res. and the Editor-in-Chief/Editors of the Journals, and hold them harmless from any loss, expense or damage occurred by a claim or suit by a third party for copyright violation, or any suit arising out of any violation of the foregoing warranties as a result of publication of my/our article. 
  8. In consideration of authors manuscript submitted, authors hereby grant Asian J. Med. Biol. Res. unlimited, worldwide, permanent royalty-free, right to publish, use, dispense, license, transmit, display, exhibit, record, store, translate, digitize, broadcast, reproduce and archive, in any format or medium, whether now known or developed hereafter.

All materials related to manuscripts, accepted or rejected, including photographs, original figures etc., will be kept by Asian J. Med. Biol. Res. for one year following the editor’s decision. These materials will then be destroyed.